Evidence map›Paper›PMID 21326832›Full record

ReviewBioengineered bugs

The Bacterial Ghost platform system: production and applications.

Timo Langemann, Verena Juliana Koller, Abbas Muhammad, Pavol Kudela, Ulrike Beate Mayr, Werner Lubitz

Open access · bronzeAbstract readReview
In one paragraph

Review in Bioengineered bugs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 193 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Bacterial ghosts (BGs): A promising approach as candidate vaccine.World journal of microbiology & biotechnology · 2026
    Review
  5. A Chemically InducedVaccines · 2026
    Article
  6. Review
  7. Oral Vaccination withVaccines · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. NovelHeliyon · 2024
    Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Bacteria-Based Nanoprobes for Cancer Therapy.International journal of nanomedicine · 2024
    Review
  19. Comparison of the immune effects of theFrontiers in microbiology · 2024
    Article
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Timo LangemannBIRD-C GmbH and CoKEG, Kritzendorf, Austria.
Verena Juliana Koller
Abbas Muhammad
Pavol Kudela
Ulrike Beate Mayr
Werner Lubitz
University of Vienna · ATInstitute for Comparative Media and Communication Studies · ATSlovak Academy of Sciences · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Bacterial Ghost (BG) platform technology is an innovative system for vaccine, drug or active substance delivery and for technical applications in white biotechnology. BGs are cell envelopes derived from Gram-negative bacteria. BGs are devoid of all cytoplasmic content but have a preserved cellular morphology including all cell surface structures. Using BGs as delivery vehicles for subunit or DNA-vaccines the particle structure and surface properties of BGs are targeting the carrier itself to primary antigen-presenting cells. Furthermore, BGs exhibit intrinsic adjuvant properties and trigger an enhanced humoral and cellular immune response to the target antigen. Multiple antigens of the native BG envelope and recombinant protein or DNA antigens can be combined in a single type of BG. Antigens can be presented on the inner or outer membrane of the BG as well as in the periplasm that is sealed during BG formation. Drugs or supplements can also be loaded to the internal lumen or periplasmic space of the carrier. BGs are produced by batch fermentation with subsequent product recovery and purification via tangential flow filtration. For safety reasons all residual bacterial DNA is inactivated during the BG production process by the use of staphylococcal nuclease A and/or the treatment with β-propiolactone. After purification BGs can be stored long-term at ambient room temperature as lyophilized product. The production cycle from the inoculation of the pre-culture to the purified BG concentrate ready for lyophilization does not take longer than a day and thus meets modern criteria of rapid vaccine production rather than keeping large stocks of vaccines. The broad spectrum of possible applications in combination with the comparably low production costs make the BG platform technology a safe and sophisticated product for the targeted delivery of vaccines and active agents as well as carrier of immobilized enzymes for applications in white biotechnology.

Indexed as

Cell MembraneDrug Delivery SystemsGene ExpressionGenetic VectorsGram-Negative BacteriaHumansVaccinesVaccinesbacterial ghostsbacterial inactivationdrug carrierE-mediated lysisfermentationtumor treatmentvaccineswhite biotechnology

Identifiers

PMID21326832
PMCPMC3037582
OpenAlexW2037745432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.